Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Fig. 4

Iron parameters with FCM vs placebo in patients with and without diabetes. Absolute change from baseline in (A) serum ferritin, (B) hemoglobin, and (C) TSAT over time with FCM vs placebo (SAS population), and (D) FCM dosing at each time point in patients with and without diabetes (mITT population). Error bars are standard error of the mean. *p < 0.05, **p < 0.01, and ***p < 0.0001 for FCM vs placebo. aNo study drug was administered after Week 24, as per the protocol. FCM ferric carboxymaltose, Hb hemoglobin, mITT modified intention-to-treat, NA not applicable, SAS safety analysis set, SD standard deviation, TSAT transferrin saturation

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840